Skip to main navigation

Sagimet Biosciences

Main navigation

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

News Releases

Year

6/29/2026

Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes

6/22/2026

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

5/27/2026

Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH

5/13/2026

Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

5/12/2026

Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

5/11/2026

Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago

4/27/2026

Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock

4/27/2026

Sagimet Biosciences Provides Strategic and Corporate Updates

4/20/2026

Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

4/6/2026

Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Pagination

Current page 1
Page 2
Next page
Last page

Site Map

About
Science
Investors
Programs
Contact

Contact Us

Business Development:
bd@sagimet.com

Investors:
ir@sagimet.com

Media:
media@sagimet.com

© 2026 Sagimet Biosciences Inc.. All Rights Reserved.

Close line1 Close line2

Main navigation

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact